Navigation Links
NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimer's
Date:12/10/2012

TEL AVIV, Israel, December 10, 2012 /PRNewswire/ --

NeuroQuest, a company of the Trendlines Group's Misgav Venture Accelerator is moving quickly towards an important validation trial for novel blood-based immune biomarkers for the diagnosis of Alzheimer's disease. The company's biomarker platform for neurodegenerative diseases is based on the research of Prof. Michal Schwartz, Chair of Neuroimmunology at the Weizmann Institute of Science who pioneered the concept of Protective AutoImmunity. The trial is a follow-up to the preliminary human trial performed at Sheba, Rambam, and Abarbanel Medical Centers in Israel and Methodist Neurological Institute in Houston, Texas which demonstrated up to 85% diagnostic accuracy and specificity in AD and ALS patients in mild to moderate stages versus healthy controls. The success of the validation trial would present a new approach for a simple, inexpensive, and early diagnosis of Alzheimer's disease. Successful results may lead to new therapeutic targets for this disease, opening new directions to an industry searching for novel approaches to combat AD, given the recent failures of several Phase III trials for therapeutics targeting Beta-Amyloid reduction.

Dr. Jacobo Mintzer, Co-Director of Alzheimer's Research & Clinical Programs of the Medical University of South Carolina, has joined the company as its new VP of Clinical affairs to leverage his experience in over 200 Alzheimer's-related clinical trials. NeuroQuest has also announced a new partnership with the Harvard Clinical Research Institute and their Senior Director of Clinical Program Management, Dr. Jennifer Buell. Together the teams are gearing up for a 150-200 patients clinical trial at MUSC, Harvard, and other medical centers to validate the company's novel immune-based biomarkers for Alzheimer's Disease.

The company has confirmed financing totaling $500,000 led by InterTech Group, headed by Jonathan Zucker, and the Maryland/Israel Trendlines Fund. The company is also in serious discussions with the South Carolina Research Authority (SCRA) about a grant to support opening a US development center in Charleston, SC as the base of its clinical and regulatory work. Many of these developments were put into motion following a 2011 American Israel Chamber of Commerce - South East's (AICC-SE) delegation from South Carolina headed by Tom Glaser. Glaser's group, returned to Israel and Misgav again this week to celebrate and investigate additional opportunities for collaboration and investment.

Contact:
Efrat Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030
Efrat@ofirpr.co.il


'/>"/>
SOURCE NeuroQuest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wright Therapy Products, Inc. Closes $3 million Financing Round
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
5. DenTech China 2012 Closed with Success
6. Agnitio Sets Up Asia HQ in Shanghai and is the First to Bring the Combined Closed Loops of Marketing and E-Learning to the Pharmaceutical Industry
7. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
8. Novelos Therapeutics Closes $2 Million Private Placement
9. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
10. RxAnte Closes Series A Financing
11. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ORANGE COUNTY, Calif. , May 27, 2016  A new study highlights the ... study conducted by the  Journal of the American College of Radiology , a majority ... particular procedures. Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic ...
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical ... Each physical therapy professional and every clinic has a duty to perform at the ... a competitive industry is also essential. The solution that many physical therapy leaders turn ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... FDAI, DAHC, CDC, has joined the Fire Door Solutions’ team. Keith will ... fire door and frame in-field re-labeling. He will be instrumental in developing ...
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis ... an event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise ... of liver cancer. , Foundation leaders and the citywide coalition they created, Hep B ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two hospital ... patients from other participating organizations in the exchange. SJMC’s membership in the health ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
Breaking Medicine News(10 mins):